［1］Zhang N，Hao CX，Wang JH，et al.Clinical characteristics and prognosis of diffuse large B-cell lymphoma：Report of 50 elderly patients［J］.Chin J Mult Organ Dis Elderly，2015，14(11)：804-808.［张娜，郝彩霞，王健红，等.老年弥漫大B细胞淋巴瘤50例患者的临床特征和预后分析［J］.中华老年多器官疾病杂志，2015，14（11）：804-808.］
［2］Barrett-Lee PJ，Dixon JM，Farrell C，et al.Expert opinion on the use of anthracyclines in patients with advanced breast cancer at cardiac risk［J］.Ann Oncol，2009，20(5)：816.
［3］Shen WN，Ji DM，Xue K，et al.A phase I dose-escalating trial of pegylated liposomal doxorubicin in combination with cyclophosphamide，vincristine and prednisone for aggressive non-Hodgkin lymphoma［J］.Chin J Hematol，2016，37(12)：1044-1048.［沈维娜，季冬梅，薛恺，等.聚乙二醇脂质体阿霉素在CHOP方案治疗侵袭性非霍奇金淋巴瘤中的I期剂量递增试验的安全性探索［J］.中华血液学杂志，2016，37（12）：1044-1048.］
［4］Theodoulou M，Hudis C.Cardiac profiles of liposomal anthracyclines：greater cardiac safety versus conventional doxorubicin［J］.Cancer，2004，100(10)：2052-2063.
［5］Grillo Lopez AJ，Cheson BD，Homing SJ，et al.Response criteria for NHL：Important of normal lymph node size and correlations with response rates［J］.Ann Oncol，2000，11：399-408.
［6］Jackson G，Taylor P，Smith GM，et al.A muhicentre，open，non-comparative phase II study of a combination of fludarabine phosphate，eytarabine and granulocyte colonystimulating factor in relapsed and refractory acute myeloid leukemia and de novo refractory anemia with excess blasts in transformation［J］.Br J Haematol，2001，112：127-137.
［7］Zaja F，Tomadinio V，Zaccaria A，et al.CHOP-rituximab with pegylated liposomal doxorubicin for the treatment of elderly patients with diffuse large B-cell lymphoma［J］.Leukemia Lymph，2006，47(10)：2174-2180.
［8］Gui L，Shi YK，Yang JL，et al.Pegylated liposomal doxorubicin in CHOP regimen for untreated elderly patients with advanced diffuse large B-cell lymphoma：results from a prospective phase II study［J］.Chin J Clin Oncol，2015，42(3)：162-166.［桂琳，石远凯，杨建良，等.含聚乙二醇脂质体多柔比星的CHOP样方案治疗初治老年晚期弥漫大B细胞淋巴瘤的II期临床研究［J］.中国肿瘤临床，2015，42（3）：162-166.］
［9］Huang JQ，Luo BH.Comparative study on the treatment of diffuse large B cell lymphoma with liposomal doxorubicin and doxorubicin［J］.Strait Pharmaceutical Journal，2016，28(7)：118-121.［黄建清，罗必华.脂质体多柔比星与多柔比星治疗弥漫大B细胞淋巴瘤的比较研究［J］.海峡药学，2016，28（7）：118-121.］
［10］Li ZH，Xing PT，Zhang YP，et al.Clinical efficiency and safety of the first-line CHOP regimen containing PLD applied to treat aged patients with advanced DLBCL［J］.J Exp Hematol，2016，24(3)：744-748.［李志慧，邢朋涛，张彦平，等.含PLD的CHOP方案用于高龄晚期DLBCL一线化疗的疗效及安全性［J］.中国实验血液学杂志，2016，24（3）：744-748.］
［11］Schmitt GJ，Dietrich S，Ho AD，et al.Replacement of conventional doxorubicin by pegylated liposomal doxorubicin is a safe and effective alternative in the treatment of non-Hodgkin's lymphoma patients with cardiac risk factors［J］.Ann Hematol，2012，91(3)：391-397.
［12］MacDonald D，Crosbie T，Christofides A，et al.A Canadian perspective on the subcutaneous administration of rituximab in non-Hodgkin lymphoma［J］.Curr Oncol，2017，24(1)：33-39.
［13］Monk BJ，Brady MF，Aghajanian C，et al.A phase 2，randomized，double-blind，placebo-controlled study of chemo-immunotherapy combination using motolimod with pegylated liposomal doxorubicin in recurrent or persistent ovarian cancer：A gynecologic oncology hroup partners study［J］.Ann Oncol，2017，28(5)：996-1004.